- Samarendra Mohanty, Co-Founder, President and Chief Scientific Officer, to participate in the premier cell and gene therapy industry conference, October 5–7, 2026, in Phoenix, Arizona
ダラス, Sept. 29, 2026 — ナノスコープ・セラピューティクス, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Samarendra Mohanty, Co-Founder, President and Chief Scientific Officer, will deliver an Innovation Spotlight presentation at the Cell & Gene Meeting on the Mesa 2026, taking place October 5–7, 2026 in Phoenix, Arizona. The meeting is organized by the Alliance for Regenerative Medicine (ARM), which unites the cell and gene therapy ecosystem to modernize healthcare systems, overcome obstacles to innovation, and improve patient access to life-changing treatments.
プレゼンテーションの詳細：
Cell & Gene Meeting on the Mesa 2026
セッション： Innovation Spotlights
プレゼンター： Samarendra Mohanty, President
日時： Tuesday, October 6, 2026, 11:15 AM
位置： The Arizona Biltmore Hotel, Phoenix, Arizona
During his presentation, Dr. Mohanty will provide a company update on Nanoscope’s progress toward potential global approval of its lead asset, MOGENRY® (sonpiretigene isteparvovec; MCO-010), for the treatment of inherited retinal dystrophies, including the status of the Company’s Biologics License Application (BLA), currently under FDA review. Members of the Nanoscope leadership will be available to meet. Investors and potential partners should schedule a meeting via the partnering App or reach out to Nanoscope directly.
About MOGENRY (sonpiretigene isteparvovec; MCO-010)
ナノスコープ社の多特性オプシン（MCO）技術は、独自の遺伝子操作合成オプシンを利用して、広範囲の光スペクトルにわたる高い光感度と高速な反応速度という点で最適な性能を実現します。ナノスコープ社の共同創業者、社長兼最高科学責任者であるサマレンドラ・モハンティ氏がこの技術を構想・発明した後、彼のチームは10年以上にわたり、複数の動物モデルとヒト疾患におけるその性能を評価してきました。MOGENRYは、ナノスコープ社のMCOプラットフォームを基盤とした、治験段階の1回限りの院内硝子体内光遺伝学的遺伝子治療です。MOGENRYは、高密度の双極網膜細胞に多特性オプシン遺伝子を投与することで、これらの生存細胞を直接光感受性にし、光受容体の喪失後も残存する視覚回路を利用できるようにします。MOGENRYは、遺伝子検査、侵襲的な手術、または繰り返し投与を必要とせず、既存の網膜診療ワークフロー内で投与できるように設計されています。.
ナノスコープ・セラピューティクスについて
Nanoscope Therapeutics is developing disease-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b/3 multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the FDA has accepted and filed the Company’s BLA for MOGENRY. If approved, MOGENRY has the potential to become the standard of care for patients with RP, administered as a one-time, in-office injection without the need for genetic testing. The Company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2026. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD, along with RMAT designation for SD, and EMA Orphan designations covering non-syndromic and syndromic rod- and cone-dominant dystrophies, as well as macular dystrophies. MCO-010 has also received Sakigake and Orphan designations for inherited retinal dystrophies (IRDs) in Japan and an Orphan designation for IRDs in Saudi Arabia. A Phase 2 program for MCO in geographic atrophy is expected to start in 2026, and other IND-ready programs include Leber congenital amaurosis (LCA).
接触：
ナノスコープ・セラピューティクス社
(817) 857-1186
PR@nanostherapeutics.com
出典 ナノスコープ・セラピューティクス